157 related articles for article (PubMed ID: 12499181)
1. Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin.
Pfister M; Zhang L; Hammarlund-Udenaes M; Sheiner LB; Gerber CM; Täuber MG; Cottagnoud P
Antimicrob Agents Chemother; 2003 Jan; 47(1):138-43. PubMed ID: 12499181
[TBL] [Abstract][Full Text] [Related]
2. Grepafloxacin against penicillin-resistant pneumococci in the rabbit meningitis model.
Gerber CM; Tovar L; Cottagnoud M; Neftel KA; Täuber MG; Cottagnoud P
J Antimicrob Chemother; 2000 Aug; 46(2):249-53. PubMed ID: 10933648
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and ocular penetration of grepafloxacin in albino and pigmented rabbits.
Perez S; Solans C; Bregante MA; Pinilla I; García MA; Honrubia F
J Antimicrob Chemother; 2002 Oct; 50(4):541-5. PubMed ID: 12356799
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis.
Lutsar I; Friedland IR; Wubbel L; McCoig CC; Jafri HS; Ng W; Ghaffar F; McCracken GH
Antimicrob Agents Chemother; 1998 Oct; 42(10):2650-5. PubMed ID: 9756771
[TBL] [Abstract][Full Text] [Related]
5. BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis.
Rodriguez-Cerrato V; Ghaffar F; Saavedra J; Michelow IC; Hardy RD; Iglehart J; Olsen K; McCracken GH
Antimicrob Agents Chemother; 2001 Nov; 45(11):3098-103. PubMed ID: 11600362
[TBL] [Abstract][Full Text] [Related]
6. Gemifloxacin is effective in experimental pneumococcal meningitis.
Smirnov A; Wellmer A; Gerber J; Maier K; Henne S; Nau R
Antimicrob Agents Chemother; 2000 Mar; 44(3):767-70. PubMed ID: 10681354
[TBL] [Abstract][Full Text] [Related]
7. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction.
Efthymiopoulos C; Bramer SL; Maroli A; Flaherty JF; Wolfe E; Bass N; Somberg K
Clin Pharmacokinet; 1997; 33 Suppl 1():25-31. PubMed ID: 9433653
[TBL] [Abstract][Full Text] [Related]
8. Theophylline and warfarin interaction studies with grepafloxacin.
Efthymiopoulos C; Bramer SL; Maroli A; Blum B
Clin Pharmacokinet; 1997; 33 Suppl 1():39-46. PubMed ID: 9433655
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
Tran JQ; Ballow CH; Forrest A; Hyatt JM; Sands MF; Peloquin CA; Schentag JJ
J Antimicrob Chemother; 2000 Mar; 45():9-17. PubMed ID: 10719007
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of grepafloxacin.
Efthymiopoulos C
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():35-43. PubMed ID: 9484872
[TBL] [Abstract][Full Text] [Related]
11. Effect of age and gender on the pharmacokinetics of grepafloxacin.
Efthymiopoulos C; Bramer SL; Maroli A
Clin Pharmacokinet; 1997; 33 Suppl 1():9-17. PubMed ID: 9433651
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model.
Destache CJ; Pakiz CB; Larsen C; Owens H; Dash AK
J Antimicrob Chemother; 2001 May; 47(5):611-5. PubMed ID: 11328772
[TBL] [Abstract][Full Text] [Related]
13. Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits.
Nau R; Schmidt T; Kaye K; Froula JL; Täuber MG
Antimicrob Agents Chemother; 1995 Mar; 39(3):593-7. PubMed ID: 7793857
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.
París MM; Hickey SM; Trujillo M; Shelton S; McCracken GH
Antimicrob Agents Chemother; 1995 Jun; 39(6):1243-6. PubMed ID: 7574509
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits.
Ostergaard C; Sørensen TK; Knudsen JD; Frimodt-Møller N
Antimicrob Agents Chemother; 1998 Jul; 42(7):1706-12. PubMed ID: 9661008
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of T-3811ME (BMS-284756), a new des-F(6)-quinolone, for treatment of meningitis caused by penicillin-resistant Streptococcus pneumoniae in rabbits.
Takahata M; Yamada H; Morita T; Furubou S; Minami S; Todo Y; Watanabe Y; Narita H
Antimicrob Agents Chemother; 2002 Jun; 46(6):1760-5. PubMed ID: 12019087
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin in the therapy of experimental pneumococcal meningitis.
Schmidt H; Dalhoff A; Stuertz K; Trostdorf F; Chen V; Schneider O; Kohlsdorfer C; Brück W; Nau R
Antimicrob Agents Chemother; 1998 Jun; 42(6):1397-407. PubMed ID: 9624483
[TBL] [Abstract][Full Text] [Related]
18. Activity of fosfomycin in a rabbit model of experimental pneumococcal meningitis.
Nau R; Zysk G; Reinert RR; Mergeryan H; Eiffert H; Prange HW
J Antimicrob Chemother; 1995 Dec; 36(6):997-1004. PubMed ID: 8821598
[TBL] [Abstract][Full Text] [Related]
19. Effect of renal impairment on the pharmacokinetics of grepafloxacin.
Efthymiopoulos C; Bramer SL; Maroli A; Gambertoglio JG
Clin Pharmacokinet; 1997; 33 Suppl 1():32-8. PubMed ID: 9433654
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis: basis for dosage selection in children with meningitis.
McCoig CC; Wubbel L; Jafri HS; Lutsar I; Bastero R; Olsen K; Shelton S; Friedland IR; McCracken GH
J Antimicrob Chemother; 1999 May; 43(5):683-8. PubMed ID: 10382890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
